Related Experiment Videos
Long-term botulinum toxin efficacy, safety, and immunogenicity
Nicte I Mejia1, Kevin Dat Vuong, Joseph Jankovic
1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA.
Summary
Long-term botulinum toxin (BTX) treatment shows sustained efficacy and safety over 12 years. Peak response duration and dose increased, with improved global ratings and fewer adverse events over time.
Area of Science:
- Neurology
- Pharmacology
- Medical Treatments
Background:
- Botulinum toxin (BTX) is widely used for various medical conditions.
- Long-term efficacy and safety data for continuous BTX treatment are limited.
- Understanding treatment durability is crucial for patient management.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of continuous botulinum toxin (BTX) treatments.
- To analyze changes in treatment response, dosage, and adverse events over an extended period.
- To assess the impact of antibodies on treatment outcomes.
Main Methods:
- Longitudinal analysis of 45 patients receiving continuous BTX for ≥12 years.
- Assessment of response rating, latency, duration, peak effect, and dose per visit.
- Evaluation of adverse events and antibody testing in nonresponsive patients.
Main Results:
- Mean response rating of 3.7/4 after a mean of 15.8 years of treatment.
- Increased peak duration of response (P < 0.005) and dose per visit (P < 0.0001).
- Improved global rating (P < 0.02) and peak effect (P < 0.05); reduced adverse events over time.
- 18% of tested patients had blocking antibodies; most nonresponders switched to BTX-B.
Conclusions:
- Continuous BTX treatment demonstrates long-term efficacy and safety.
- Treatment effectiveness, indicated by peak response and global ratings, can improve over time.
- Antibody formation is a factor in nonresponse, but alternative treatments like BTX-B are effective.